Cell Repair in Heart Failure
Heart Failure, Ischemia
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Symptomatic ischaemic multi-vessel coronary artery disease (CAD) not suitable for standard revascularization procedures such as CABG, PCI, LVAD, or heart transplant. Area of reversible inducible ischaemia (>10% of LV on SPECT) performed not more than six months prior to study treatment. LVEF < 45% on optimal medical therapy. NYHA class II- IV patient stable on optimal medical therapy for at least 30 days. Written informed consent and agree to attend hospital appointments for 1 year. Male and females 18 to 80 years of age. Exclusion Criteria: Left ventricular aneurysm or thrombus. Thoracic aortic aneurysm. Congenital Heart disease Acute unstable angina, idiopathic cardiomyopathy, life-threatening ventricular arrhythmias, recent (less than 6 weeks). Contraindication to MRI or any other study procedure. Presence or history of cancer (except low grade and fully resolved non-melanoma skin malignancy). Any co-morbidity likely to reduce short- term survival or which may interfere with functional testing. Recent myocardial infarction < 6mths. Cerebral vascular accident < 6mths. Active hepatitis, receiving immunosuppressive therapy, undergoing haemodialysis. Clinically significant abnormal haematology. Recent history of alcoholism, drug abuse, or severe emotional, behavioural, or psychiatric problems. Fertile women who are pregnant, nursing, or using no form of contraception. Receiving experimental medications or participating in another study within 12 weeks of enrolment into this study.
Sites / Locations
- The Department of Gene Therapy, The National Heart and Lung Institute, Imperial College London and The Royal Brompton Hospital.